pharmexx uk limited
pharmexx uk limited Company Information
Company Number
02456441
Next Accounts
Sep 2025
Shareholders
udg healthcare (uk) holdings limited
Group Structure
View All
Industry
Activities of employment placement agencies (other than motion picture, television and other theatrical casting) n.e.c.
+1Registered Address
8th floor holborn gate, 26 southampton buildings, london, WC2A 1AN
Website
http://www.pharmexx.co.ukpharmexx uk limited Estimated Valuation
Pomanda estimates the enterprise value of PHARMEXX UK LIMITED at £1m based on a Turnover of £4m and 0.26x industry multiple (adjusted for size and gross margin).
pharmexx uk limited Estimated Valuation
Pomanda estimates the enterprise value of PHARMEXX UK LIMITED at £1.5m based on an EBITDA of £610.5k and a 2.51x industry multiple (adjusted for size and gross margin).
pharmexx uk limited Estimated Valuation
Pomanda estimates the enterprise value of PHARMEXX UK LIMITED at £1.8m based on Net Assets of £1.1m and 1.71x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Pharmexx Uk Limited Overview
Pharmexx Uk Limited is a live company located in london, WC2A 1AN with a Companies House number of 02456441. It operates in the other activities of employment placement agencies sector, SIC Code 78109. Founded in December 1989, it's largest shareholder is udg healthcare (uk) holdings limited with a 100% stake. Pharmexx Uk Limited is a mature, small sized company, Pomanda has estimated its turnover at £4m with low growth in recent years.
Upgrade for unlimited company reports & a free credit check
Pharmexx Uk Limited Health Check
Pomanda's financial health check has awarded Pharmexx Uk Limited a 3 rating. We use a traffic light system to show it exceeds the industry average on 2 measures and has 6 areas for improvement. Company Health Check FAQs
2 Strong
3 Regular
6 Weak
Size
annual sales of £4m, make it smaller than the average company (£7.8m)
£4m - Pharmexx Uk Limited
£7.8m - Industry AVG
Growth
3 year (CAGR) sales growth of 1%, show it is growing at a slower rate (6.6%)
1% - Pharmexx Uk Limited
6.6% - Industry AVG
Production
with a gross margin of 11.3%, this company has a higher cost of product (31.6%)
11.3% - Pharmexx Uk Limited
31.6% - Industry AVG
Profitability
an operating margin of 10% make it more profitable than the average company (4.8%)
10% - Pharmexx Uk Limited
4.8% - Industry AVG
Employees
with 43 employees, this is similar to the industry average (36)
43 - Pharmexx Uk Limited
36 - Industry AVG
Pay Structure
on an average salary of £59.2k, the company has an equivalent pay structure (£55.5k)
£59.2k - Pharmexx Uk Limited
£55.5k - Industry AVG
Efficiency
resulting in sales per employee of £92.9k, this is less efficient (£179.8k)
£92.9k - Pharmexx Uk Limited
£179.8k - Industry AVG
Debtor Days
it gets paid by customers after 40 days, this is near the average (43 days)
40 days - Pharmexx Uk Limited
43 days - Industry AVG
Creditor Days
its suppliers are paid after 2 days, this is quicker than average (20 days)
2 days - Pharmexx Uk Limited
20 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Pharmexx Uk Limited
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 3 weeks, this is less cash available to meet short term requirements (16 weeks)
3 weeks - Pharmexx Uk Limited
16 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 55.3%, this is a lower level of debt than the average (64.9%)
55.3% - Pharmexx Uk Limited
64.9% - Industry AVG
PHARMEXX UK LIMITED financials
Pharmexx Uk Limited's latest turnover from December 2023 is £4 million and the company has net assets of £1.1 million. According to their latest financial statements, Pharmexx Uk Limited has 43 employees and maintains cash reserves of £81.5 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2023 | Dec 2022 | Dec 2021 | Sep 2020 | Sep 2019 | Sep 2018 | Sep 2017 | Sep 2016 | Sep 2015 | Sep 2014 | Sep 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 3,993,763 | 4,964,104 | 5,100,869 | 3,833,743 | 3,498,850 | 3,419,426 | 5,684,623 | 7,578,735 | 11,148,657 | 12,877,683 | 9,735,280 | 11,528,242 | 8,642,677 | 8,199,363 | 10,748,684 |
| Other Income Or Grants | |||||||||||||||
| Cost Of Sales | 3,543,232 | 4,361,727 | 4,255,523 | 3,311,767 | 3,096,085 | 2,940,724 | 4,788,246 | 6,131,704 | 8,911,125 | 10,360,864 | 8,017,396 | 9,549,368 | 7,074,390 | 6,478,976 | 8,181,320 |
| Gross Profit | 450,531 | 602,377 | 845,346 | 521,976 | 402,765 | 478,702 | 896,377 | 1,447,031 | 2,237,532 | 2,516,819 | 1,717,884 | 1,978,874 | 1,568,287 | 1,720,387 | 2,567,364 |
| Admin Expenses | 51,123 | 206,673 | 256,113 | 151,535 | 383,225 | 963,401 | 1,055,589 | 1,597,317 | 1,762,041 | 1,270,682 | 1,569,638 | 1,352,343 | 1,700,544 | 1,109,594 | |
| Operating Profit | 399,408 | 395,704 | 589,233 | 370,441 | 19,540 | -67,024 | 391,442 | 640,215 | 754,778 | 447,202 | 409,236 | 215,944 | 19,843 | 1,457,770 | |
| Interest Payable | 10,657 | 10,494 | 7,640 | 3,663 | 153 | 179 | 7,829 | ||||||||
| Interest Receivable | 211 | 4,226 | 7,728 | 4,014 | 20,977 | 58,600 | |||||||||
| Pre-Tax Profit | 388,751 | 385,210 | 581,593 | 366,778 | 19,540 | -298,843 | -67,024 | 391,442 | 640,215 | 754,836 | 451,428 | 416,964 | -713,780 | 40,641 | 1,508,541 |
| Tax | -93,687 | -75,031 | -112,021 | -70,569 | -3,192 | 55,787 | 12,891 | -82,424 | -134,473 | -176,606 | -77,590 | -74,304 | -5,979 | -22,813 | -328,851 |
| Profit After Tax | 295,064 | 310,179 | 469,572 | 296,209 | 16,348 | -243,056 | -54,133 | 309,018 | 505,742 | 578,230 | 373,838 | 342,660 | -719,759 | 17,828 | 1,179,690 |
| Dividends Paid | 300,000 | 200,000 | 200,000 | 900,000 | 1,050,000 | 1,299,237 | 678,443 | 353,240 | |||||||
| Retained Profit | -4,936 | 310,179 | 269,572 | 96,209 | 16,348 | -243,056 | -54,133 | -590,982 | -544,258 | 578,230 | -925,399 | -335,783 | -1,072,999 | 17,828 | 1,179,690 |
| Employee Costs | 2,543,631 | 3,064,559 | 3,408,998 | 2,423,209 | 2,189,069 | 2,324,772 | 3,546,559 | 4,620,677 | 7,318,560 | 8,549,516 | 6,801,847 | 8,092,370 | 6,062,539 | 5,740,524 | 6,618,522 |
| Number Of Employees | 43 | 55 | 55 | 49 | 48 | 44 | 72 | 94 | 144 | 165 | 167 | 171 | 132 | 132 | 163 |
| EBITDA* | 610,513 | 643,362 | 842,190 | 370,807 | 20,999 | -56,804 | 407,765 | 674,668 | 793,369 | 465,181 | 437,083 | 238,233 | 37,942 | 1,481,246 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2023 | Dec 2022 | Dec 2021 | Sep 2020 | Sep 2019 | Sep 2018 | Sep 2017 | Sep 2016 | Sep 2015 | Sep 2014 | Sep 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 392,327 | 189,390 | 3,649 | 5,108 | 11,426 | 20,292 | 56,188 | 80,045 | 104,941 | 110,827 | 107,098 | 72,696 | 97,753 | ||
| Intangible Assets | 333,910 | 262,636 | |||||||||||||
| Investments & Other | 6,478 | 8,102 | |||||||||||||
| Debtors (Due After 1 year) | |||||||||||||||
| Total Fixed Assets | 340,388 | 270,738 | 392,327 | 189,390 | 3,649 | 5,108 | 11,426 | 20,292 | 56,188 | 80,045 | 104,941 | 110,827 | 107,098 | 72,696 | 97,753 |
| Stock & work in progress | |||||||||||||||
| Trade Debtors | 447,887 | 527,017 | 409,833 | 720,278 | 944,799 | 412,417 | 960,470 | 805,854 | 1,346,507 | 1,164,796 | 1,733,582 | 1,228,695 | 973,404 | 425,280 | 929,322 |
| Group Debtors | 1,500,500 | 1,191,622 | 209,422 | 1,092 | 110,343 | 64,703 | 13,248 | 2,656 | 616 | 23,486 | 23,486 | 1,298,098 | 2,138,568 | 3,058,907 | 2,891,757 |
| Misc Debtors | 35,930 | 68,703 | 186,987 | 200,234 | 246,040 | 342,321 | 525,551 | 273,587 | 312,962 | 373,065 | 402,517 | 481,005 | 440,533 | 133,054 | 129,240 |
| Cash | 81,519 | 269,499 | 604,263 | 154,672 | 174,715 | 1,032,205 | 2,716,948 | 2,844,280 | 1,659,272 | 1,049,932 | 172,055 | 620,938 | 587,131 | ||
| misc current assets | |||||||||||||||
| total current assets | 2,065,836 | 2,056,841 | 1,410,505 | 1,076,276 | 1,301,182 | 819,441 | 1,673,984 | 2,114,302 | 4,377,033 | 4,405,627 | 3,818,857 | 4,057,730 | 3,724,560 | 4,238,179 | 4,537,450 |
| total assets | 2,406,224 | 2,327,579 | 1,802,832 | 1,265,666 | 1,304,831 | 824,549 | 1,685,410 | 2,134,594 | 4,433,221 | 4,485,672 | 3,923,798 | 4,168,557 | 3,831,658 | 4,310,875 | 4,635,203 |
| Bank overdraft | 23,345 | 109,052 | |||||||||||||
| Bank loan | |||||||||||||||
| Trade Creditors | 23,474 | 2,569 | 18,744 | 7,634 | 15,003 | 109,535 | 2,373 | 54,673 | 144,685 | 170,020 | 144,602 | 65,054 | 88,395 | 54,085 | 115,961 |
| Group/Directors Accounts | 45,138 | 38,910 | 41,659 | 49,897 | 154,358 | 26,014 | 57,052 | 56,834 | 26,614 | 100 | 100 | 724 | 6,526 | 12,321 | 6,153 |
| other short term finances | |||||||||||||||
| hp & lease commitments | 196,954 | 146,921 | 217,831 | 108,299 | |||||||||||
| other current liabilities | 923,389 | 950,140 | 578,048 | 520,884 | 708,602 | 192,773 | 995,831 | 1,338,800 | 2,986,653 | 2,496,025 | 2,537,799 | 1,916,080 | 1,215,342 | 656,580 | 938,439 |
| total current liabilities | 1,188,955 | 1,138,540 | 856,282 | 686,714 | 901,308 | 437,374 | 1,055,256 | 1,450,307 | 3,157,952 | 2,666,145 | 2,682,501 | 1,981,858 | 1,310,263 | 722,986 | 1,060,553 |
| loans | |||||||||||||||
| hp & lease commitments | 142,722 | 109,556 | 177,246 | 79,220 | |||||||||||
| Accruals and Deferred Income | |||||||||||||||
| other liabilities | |||||||||||||||
| provisions | 20,003 | 18,916 | 12,411 | 17,000 | |||||||||||
| total long term liabilities | 142,722 | 109,556 | 177,246 | 79,220 | 20,003 | 18,916 | 12,411 | 17,000 | |||||||
| total liabilities | 1,331,677 | 1,248,096 | 1,033,528 | 765,934 | 901,308 | 437,374 | 1,055,256 | 1,450,307 | 3,157,952 | 2,666,145 | 2,682,501 | 2,001,861 | 1,329,179 | 735,397 | 1,077,553 |
| net assets | 1,074,547 | 1,079,483 | 769,304 | 499,732 | 403,523 | 387,175 | 630,154 | 684,287 | 1,275,269 | 1,819,527 | 1,241,297 | 2,166,696 | 2,502,479 | 3,575,478 | 3,557,650 |
| total shareholders funds | 1,074,547 | 1,079,483 | 769,304 | 499,732 | 403,523 | 387,175 | 630,154 | 684,287 | 1,275,269 | 1,819,527 | 1,241,297 | 2,166,696 | 2,502,479 | 3,575,478 | 3,557,650 |
| Dec 2023 | Dec 2022 | Dec 2021 | Sep 2020 | Sep 2019 | Sep 2018 | Sep 2017 | Sep 2016 | Sep 2015 | Sep 2014 | Sep 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||
| Operating Profit | 399,408 | 395,704 | 589,233 | 370,441 | 19,540 | -67,024 | 391,442 | 640,215 | 754,778 | 447,202 | 409,236 | 215,944 | 19,843 | 1,457,770 | |
| Depreciation | 211,105 | 247,658 | 252,957 | 366 | 1,459 | 6,318 | 10,220 | 16,323 | 34,453 | 38,591 | 17,979 | 27,847 | 22,289 | 18,099 | 23,476 |
| Amortisation | |||||||||||||||
| Tax | -93,687 | -75,031 | -112,021 | -70,569 | -3,192 | 55,787 | 12,891 | -82,424 | -134,473 | -176,606 | -77,590 | -74,304 | -5,979 | -22,813 | -328,851 |
| Stock | |||||||||||||||
| Debtors | 196,975 | 981,100 | -115,362 | -379,578 | 481,741 | -679,828 | 417,172 | -577,988 | 98,738 | -598,238 | -848,213 | -544,707 | -64,736 | -333,078 | 3,950,319 |
| Creditors | 20,905 | -16,175 | 11,110 | -7,369 | -94,532 | 107,162 | -52,300 | -90,012 | -25,335 | 25,418 | 79,548 | -23,341 | 34,310 | -61,876 | 115,961 |
| Accruals and Deferred Income | -26,751 | 372,092 | 57,164 | -187,718 | 515,829 | -803,058 | -342,969 | -1,647,853 | 490,628 | -41,774 | 621,719 | 700,738 | 558,762 | -281,859 | 938,439 |
| Deferred Taxes & Provisions | -20,003 | 1,087 | 6,505 | -4,589 | 17,000 | ||||||||||
| Cash flow from operations | 314,005 | -56,852 | 913,805 | 484,729 | -42,637 | -856,354 | -834,536 | 906,750 | 1,198,645 | 1,917,068 | 1,585,970 | 896,567 | -117 | -1,726,524 | |
| Investing Activities | |||||||||||||||
| capital expenditure | |||||||||||||||
| Change in Investments | -1,624 | 8,102 | |||||||||||||
| cash flow from investments | |||||||||||||||
| Financing Activities | |||||||||||||||
| Bank loans | |||||||||||||||
| Group/Directors Accounts | 6,228 | -2,749 | -8,238 | -104,461 | 128,344 | -31,038 | 218 | 30,220 | 26,514 | -624 | -5,802 | -5,795 | 6,168 | 6,153 | |
| Other Short Term Loans | |||||||||||||||
| Long term loans | |||||||||||||||
| Hire Purchase and Lease Commitments | 83,199 | -138,600 | 207,558 | 187,519 | |||||||||||
| other long term liabilities | |||||||||||||||
| share issue | |||||||||||||||
| interest | -10,657 | -10,494 | -7,640 | -3,663 | 58 | 20,798 | 50,771 | ||||||||
| cash flow from financing | 78,770 | -151,843 | 191,680 | 79,395 | 128,344 | -30,961 | 218 | 30,220 | 26,514 | 58 | 26,966 | 2,434,884 | |||
| cash and cash equivalents | |||||||||||||||
| cash | -187,980 | -334,764 | 449,591 | 154,672 | -174,715 | -857,490 | -1,684,743 | -127,332 | 1,185,008 | 609,340 | 877,877 | -448,883 | 33,807 | 587,131 | |
| overdraft | -23,345 | -85,707 | 109,052 | ||||||||||||
| change in cash | -187,980 | -334,764 | 449,591 | 178,017 | 85,707 | -283,767 | -857,490 | -1,684,743 | -127,332 | 1,185,008 | 609,340 | 877,877 | -448,883 | 33,807 | 587,131 |
pharmexx uk limited Credit Report and Business Information
Pharmexx Uk Limited Competitor Analysis
Perform a competitor analysis for pharmexx uk limited by selecting its closest rivals, whether from the ADMINISTRATIVE AND SUPPORT SERVICE ACTIVITIES sector, other small companies, companies in WC2A area or any other competitors across 12 key performance metrics.
pharmexx uk limited Ownership
PHARMEXX UK LIMITED group structure
Pharmexx Uk Limited has no subsidiary companies.
Ultimate parent company
CLAYTON, DUBILIER & RICE HOLDINGS LLC
#0162100
2 parents
PHARMEXX UK LIMITED
02456441
pharmexx uk limited directors
Pharmexx Uk Limited currently has 2 directors. The longest serving directors include Ms Jade Thiravithul (Dec 2019) and Mr Andrew Morrow (Oct 2023).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Ms Jade Thiravithul | England | 46 years | Dec 2019 | - | Director |
| Mr Andrew Morrow | England | 57 years | Oct 2023 | - | Director |
P&L
December 2023turnover
4m
-20%
operating profit
399.4k
+1%
gross margin
11.3%
-7.04%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2023net assets
1.1m
0%
total assets
2.4m
+0.03%
cash
81.5k
-0.7%
net assets
Total assets minus all liabilities
pharmexx uk limited company details
company number
02456441
Type
Private limited with Share Capital
industry
78109 - Activities of employment placement agencies (other than motion picture, television and other theatrical casting) n.e.c.
82990 - Other business support service activities n.e.c.
incorporation date
December 1989
age
36
incorporated
UK
ultimate parent company
accounts
Audit Exemption Subsidiary
last accounts submitted
December 2023
previous names
pharmexx alchemy limited (January 2011)
alchemy pharma consultancy limited (November 2008)
accountant
-
auditor
-
address
8th floor holborn gate, 26 southampton buildings, london, WC2A 1AN
Bank
NATIONAL WESTMINSTER BANK PLC
Legal Advisor
-
pharmexx uk limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 2 charges/mortgages relating to pharmexx uk limited. Currently there are 2 open charges and 0 have been satisfied in the past.
pharmexx uk limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for PHARMEXX UK LIMITED. This can take several minutes, an email will notify you when this has completed.
pharmexx uk limited Companies House Filings - See Documents
| date | description | view/download |
|---|
